Showing results (431-440 of 441) with videos related to
Sort By:
Pageof 45
The New England Journal of Medicine|August 13, 2015
A Randomized Trial of Intrapartum Fetal ECG ST-Segment AnalysisMichael A Belfort, George R Saade, Elizabeth Thom, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxAlexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.Pageof 45